TrialCardiovascular diabetology2017

Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data.

Michael J Davies et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.